2024
Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Nagpal S, Milano M, Chiang V, Soltys S, Brackett A, Halasz L, Garg A, Sahgal A, Ahluwalia M, Tom M, Palmer J, Knisely J, Chao S, Gephart M, Wang T, Lo S, Chang E. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer. Neuro-Oncology 2024, 26: 1195-1212. PMID: 38459978, PMCID: PMC11226873, DOI: 10.1093/neuonc/noae041.Peer-Reviewed Original ResearchNon-small cell lung cancerTyrosine kinase inhibitorsCell lung cancerCentral nervous systemAmerican Radium SocietyALK-fusionBrain metastasesAmerican Radium Society Appropriate Use CriteriaLung cancerSequence of tyrosine kinase inhibitorsALK tyrosine kinase inhibitorsTreatment of brain metastasesEGFR tyrosine kinase inhibitorsWhole-brain RTEpidermal growth factor receptorGrowth factor receptorAppropriate Use CriteriaBrain RTEGFR-mutantRadiotherapyTreatment optionsFactor receptorKinase inhibitorsNervous systemLiterature search
2023
PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study
Kaur M, Petersen G, Jekel L, von Reppert M, Varghese S, de Oliveira Santo I, Avesta A, Aneja S, Omuro A, Chiang V, Aboian M. PACS-Integrated Tools for Peritumoral Edema Volumetrics Provide Additional Information to RANO-BM-Based Assessment of Lung Cancer Brain Metastases after Stereotactic Radiotherapy: A Pilot Study. Cancers 2023, 15: 4822. PMID: 37835516, PMCID: PMC10571649, DOI: 10.3390/cancers15194822.Peer-Reviewed Original ResearchPost-SRTStereotactic radiotherapyLung cancer brain metastasesCancer brain metastasesPost-contrast T1-weighted imagesSignificant clinical symptomsContrast-enhancing tumorT1-weighted imagesCritical additional informationEdema changesBrain metastasesClinical symptomsCare treatmentHyperintense volumeEdema assessmentLesion changesLesion sizeEdemaDifferent timepointsPilot studyRadiotherapyLesionsVolumetric changesAdditional informationMETS
2018
SURG-15. UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS
Mohammadi A, Sharma M, Beaumont T, Juarez K, Kemeny H, Dechant C, Seas A, Sarmey N, Lee B, Jia X, Fecci P, Baehring J, Moliterno J, Chiang V, Ahluwalia M, Kim A, Barnett G, Leuthardt E. SURG-15. UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS. Neuro-Oncology 2018, 20: vi253-vi254. PMCID: PMC6216291, DOI: 10.1093/neuonc/noy148.1051.Peer-Reviewed Original Research
2013
Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases
Husain ZA, Thibault I, Letourneau D, Ma L, Keller H, Suh J, Chiang V, Chang EL, Rampersaud RK, Perry J, Larson DA, Sahgal A. Stereotactic body radiotherapy: a new paradigm in the management of spinal metastases. CNS Oncology 2013, 2: 259-270. PMID: 25054466, PMCID: PMC6166530, DOI: 10.2217/cns.13.11.Peer-Reviewed Original ResearchConceptsSpine stereotactic body radiotherapyStereotactic body radiotherapyBody radiotherapySpinal metastasesMajor serious adverse eventsRole of surgerySerious adverse eventsConventional palliative radiotherapyPain controlPalliative radiotherapyAdverse eventsClinical outcomesConventional radiotherapyRadiotherapyEffective dosesMetastasisPatientsSurgeryTumorsDoses